Mikko Kuoppamäki
Orion Corporation
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mikko Kuoppamäki.
European Journal of Neurology | 2009
Helena Nissinen; Mikko Kuoppamäki; M. Leinonen; A. H. V. Schapira
Background: We analysed data from three clinical trials in Parkinson’s disease (PD) patients with wearing‐off to determine whether early enhancement of levodopa therapy with entacapone can lead to better long‐term outcomes than delayed entacapone treatment.
Current Therapeutic Research-clinical and Experimental | 2015
Matti Kivikko; Mikko Kuoppamäki; Lauri Soinne; Stig Sundberg; Pasi Pohjanjousi; Juha Ellmen; Risto O. Roine
Background Intravenous levosimendan is indicated for acute heart failure. The compound has shown promising beneficial effects in ischemic stroke models. Objective We evaluated the efficacy and safety of oral levosimendan in patients with a history of cerebral ischemia. Methods In a randomized, double-blind, placebo-controlled, parallel-group study, 16 patients with a history of ischemic stroke/transient ischemic attack received oral levosimendan in 5 escalating doses from 0.125 to 2.0 mg daily for 18-day intervals of each dose; 5 patients received placebo. Twenty-four-hour ambulatory ECG and cerebral blood flow velocities using transcranial Doppler ultrasound were recorded at baseline and at the end of each dosing period. Vasomotor reactivity was assessed via the breath holding index. In addition, plasma levels of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) and the metabolites of levosimendan were determined. Results Levosimendan induced an increase in cerebral blood flow velocities and a decrease in NT-pro-BNP compared with placebo. There was no significant effect on breath holding index. Doses ≥0.5 mg increased heart rate by 5 to 9 beats/min. The dose level of 2.0 mg exceeded the preset safety margin of ventricular extrasystoles per hour (ie, upper 90% CI of the ratio of levosimendan to placebo above 2) with an estimate of 3.10 (90% CI, 0.95–10.07). Conclusions Oral levosimendan increases cerebral blood flow velocities and diminishes NT-pro-BNP levels in patients with earlier ischemic cerebrovascular event. Daily doses up to 1.0 mg were well tolerated, whereas the 2.0 mg dose level induced an increase in ventricular extrasystoles. ClinicalTrials.gov identifier: NCT00698763.
Acta Neurologica Scandinavica | 2014
Mikko Kuoppamäki; Mikko Vahteristo; Juha Ellmen; Karl Kieburtz
To investigate efficacy and safety of entacapone across phase III studies in Parkinsons disease (PD) with wearing‐off symptoms.
European Journal of Pharmacology | 2015
Jouko Levijoki; Matti Kivikko; Piero Pollesello; Jukka Sallinen; Minja Hyttilä-Hopponen; Mikko Kuoppamäki; Kristiina Haasio; Olli Gröhn; Riitta Miettinen; Jukka Puoliväli; Leena Tähtivaara; Juha Yrjänheikki; Antti Haapalinna
The effects of levosimendan on cerebrovascular lesions and mortality were investigated in models of primary and secondary stroke. We aimed to determine whether the effects of levosimendan are comparable to and/or cumulative with those of valsartan, and to investigate whether levosimendan-induced vasodilation has a role in its effects on stroke. In a primary stroke Dahl/Rapp rat model, mortality rates were 70% and 5% for vehicle and levosimendan, respectively. Both stroke incidence (85% vs. 10%, P<0.001) and stroke-associated behavioral deficits (7-point neuroscore: 4.59 vs. 5.96, P<0.001) were worse for vehicle compared to levosimendan. In a secondary stroke model in which levosimendan treatment was started after cerebrovascular incidences were already detected, mean survival times were 15 days with vehicle, 20 days with levosimendan (P=0.025, vs. vehicle), 22 days with valsartan (P=0.001, vs. vehicle), and 31 days with levosimendan plus valsartan (P<0.001, vs. vehicle). The respective survivals were 0%, 16%, 20% and 59%, and the respective incidences of severe lesions were 50%, 67%, 50% and 11%. In this rat model, levosimendan increased blood volume of the cerebral vessels, with significant effects in the microvessels of the cortex (∆R=3.5±0.15 vs. 2.7±0.17ml for vehicle; P=0.001) and hemisphere (∆R=3.2±0.23 vs. 2.6±0.14ml for vehicle; P=0.018). Overall, levosimendan significantly reduced stroke-induced mortality and morbidity, both alone and with valsartan, with apparent cumulative effects, an activity in which the vasodilatory effects of levosimendan have a role.
Movement Disorders | 2015
Pasi Korhonen; Mikko Kuoppamäki; Tuire Prami; Fabian Hoti; Solomon Christopher; Juha Ellmen; Valtteri Aho; Mikko Vahteristo; Eero Pukkala; Jari Haukka
The association between Parkinsons disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE‐PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol‐O‐methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.
European Journal of Clinical Pharmacology | 2009
Mikko Kuoppamäki; Kirsi Korpela; Reijo J. Marttila; Valtteri Kaasinen; Päivi Hartikainen; Jukka Lyytinen; Seppo Kaakkola; Jutta Hänninen; Eliisa Löyttyniemi; Marita Kailajärvi; Päivi Ruokoniemi; Juha Ellmen
Journal of Neural Transmission | 2008
David J. Brooks; Mika Leinonen; Mikko Kuoppamäki; Helena Nissinen
Archive | 2008
Jukka Sallinen; Mikko Kuoppamäki; Jouko Levijoki
Archive | 2011
Juha Rouru; Mikko Kuoppamäki; Juha Ellmen; Pekka Männistö
Journal of Neural Transmission | 2015
Mikko Kuoppamäki; Mika Leinonen; Werner Poewe